Odette S Reifsnider
5PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Feb 16, 2024
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.Odette S Reifsnider, Ali Tafazzoli, Stephan Linden
|Dec 15, 2021
Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.Odette S Reifsnider, Pratik Pimple, Sarah Brand
|May 04, 2021
Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.Odette S Reifsnider, Anuraag R Kansal, Pranav K Gandhi
|Nov 25, 2020
Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.Odette Reifsnider, Anuraag Kansal, Pratik Pimple
|Sep 10, 2020
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.Odette S Reifsnider, Anuraag R Kansal, Jennifer Franke
Pageof 1
